ViaDerma (VDRM) Stock Price, News & Analysis

Company Overview

ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.

Key Stats

• Today's Range: $0.0114 to $0.0124
• 50-Day Range: $0.0074 to $0.0121
• 52-Week Range: $0.0025 to $0.0150
• Volume: 2.22 million shs
• Average Volume: 3.27 million shs
• Market Capitalization: N/A
• P/E Ratio: 0.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ViaDerma Stock Analysis - MarketRank™

ViaDerma scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ViaDerma.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ViaDerma is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.71.

Price to Earnings Ratio vs. Sector

The P/E ratio of ViaDerma is 0.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.69.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

ViaDerma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ViaDerma does not currently pay a dividend.

Dividend Growth

ViaDerma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

ViaDerma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ViaDerma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ViaDerma insiders have not sold or bought any company stock.

Percentage Held by Insiders

65.70% of the stock of ViaDerma is held by insiders. A high percentage of insider ownership can be a sign of company health.

VDRM Stock Analysis - Frequently Asked Questions

How have VDRM shares performed this year?

ViaDerma's stock was trading at $0.0074 at the start of the year. Since then, VDRM stock has increased by 66.2% and is now trading at $0.0123.
View the best growth stocks for 2025 here.

How do I buy shares of ViaDerma?

Shares of VDRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ViaDerma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ViaDerma investors own include Tesla (TSLA), Dominari (DOMH), Co-Diagnostics (CODX), CEA Industries (CEAD), Organicell Regenerative Medicine (BPSR), Vinco Ventures (BBIG) and AutoZone (AZO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VDRM
• CUSIP: N/A
• CIK: N/A
• Web: viadermalicensing.com
• Phone: (310) 734-6111
• Fax: N/A
• Employees: 75
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A